A recent study published in The Journal of Nuclear Medicine demonstrates that differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery experience improved relative survival rates compared to those who do not. The research indicates that this trend is particularly evident in low- and intermediate-risk patients, with significant benefits noted in high-risk cases. Analyzing data from over 101,000 patients, the study found that relative survival rates tended to be higher for most subgroups receiving RAI therapy, with some high-risk patients seeing benefits of up to 30.9% in relative survival. This evidence supports the continued use of RAI therapy as a treatment option for thyroid cancer, potentially guiding physicians in their treatment recommendations.
Tue, 13 May 2025 01:30:26 GMT | Medical Dialogues